Skip to main content

Table 3 The adverse events after intaking of sorafenib [the number of cases (%)]

From: The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma

CTCAE grade

I

II

III

Symptom

Number (%)

Number (%)

Number (%)

Hand-foot skin reaction

10

(22.2)

15

(33.3)

12

(26.7)

Rash

19

(42.2)

5

(11.1)

2

(4.44)

Diarrhea

17

(37.8)

4

(8.89)

1

(2.22)

Hair loss

17

(37.8)

2

(4.44)

2

(4.44)

Hypertension

15

(33.3)

7

(15.6)

3

(6.67)

Fatigue

22

(48.9)

3

(6.67)

0

(0)

Anorexia

12

(26.7)

2

(4.44)

0

(0)

Nausea

11

(24.4)

1

(2.22)

0

(0)

Depression

9

(20)

0

(0)

0

(0)

Muscle aches

14

(31.1)

0

(0)

0

(0)